EG25613A - Thienopyrimidinediones and their use in the modulation of autoimmune disease - Google Patents

Thienopyrimidinediones and their use in the modulation of autoimmune disease

Info

Publication number
EG25613A
EG25613A EGNA2005000380A EG25613A EG 25613 A EG25613 A EG 25613A EG NA2005000380 A EGNA2005000380 A EG NA2005000380A EG 25613 A EG25613 A EG 25613A
Authority
EG
Egypt
Prior art keywords
thienopyrimidinediones
sup
modulation
autoimmune disease
compounds
Prior art date
Application number
Other languages
English (en)
Inventor
Simon David Guile
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of EG25613A publication Critical patent/EG25613A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EGNA2005000380 2003-01-17 2005-07-12 Thienopyrimidinediones and their use in the modulation of autoimmune disease EG25613A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300119A SE0300119D0 (sv) 2003-01-17 2003-01-17 Novel compounds
PCT/SE2004/000052 WO2004065394A1 (en) 2003-01-17 2004-01-15 Thienopyrimidinediones and their use in the modulation of autoimmune disease

Publications (1)

Publication Number Publication Date
EG25613A true EG25613A (en) 2012-03-22

Family

ID=20290154

Family Applications (1)

Application Number Title Priority Date Filing Date
EGNA2005000380 EG25613A (en) 2003-01-17 2005-07-12 Thienopyrimidinediones and their use in the modulation of autoimmune disease

Country Status (24)

Country Link
US (2) US7384951B2 (ko)
EP (1) EP1587812B1 (ko)
JP (1) JP4519121B2 (ko)
KR (2) KR101107486B1 (ko)
CN (1) CN100334093C (ko)
AT (1) ATE335748T1 (ko)
AU (1) AU2004206012B2 (ko)
BR (1) BRPI0406801B8 (ko)
CA (1) CA2512441C (ko)
DE (1) DE602004001857T2 (ko)
EG (1) EG25613A (ko)
ES (1) ES2270337T3 (ko)
HK (1) HK1081959A1 (ko)
IL (1) IL169370A (ko)
IS (1) IS2376B (ko)
MX (1) MXPA05007496A (ko)
NO (1) NO333702B1 (ko)
NZ (1) NZ541217A (ko)
PL (1) PL214682B1 (ko)
RU (1) RU2331647C2 (ko)
SE (1) SE0300119D0 (ko)
UA (1) UA81788C2 (ko)
WO (1) WO2004065394A1 (ko)
ZA (1) ZA200505364B (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
RU2332420C2 (ru) * 2003-01-17 2008-08-27 Астразенека Аб Тиенопиримидиндионы и их применение в модулировании аутоиммунного заболевания
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
CA2608733A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
PL1893612T3 (pl) 2005-06-22 2012-01-31 Plexxikon Inc Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
AU2007336811A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
GB0713479D0 (en) * 2007-07-11 2007-08-22 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
PT2411395E (pt) * 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Derivados de furopirimidinadiona como moduladores de trpa1
AP2011005888A0 (en) * 2009-03-23 2011-10-31 Glenmark Pharmaceuticals Sa Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators.
WO2010114928A2 (en) 2009-04-03 2010-10-07 F.Hoffmann-La Roche Ag Compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
ES2633317T3 (es) 2009-11-06 2017-09-20 Plexxikon, Inc. Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
EP2804852A2 (en) 2012-01-20 2014-11-26 Regents Of The University Of Minnesota Therapeutic compounds
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014172627A1 (en) 2013-04-19 2014-10-23 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
EA030962B1 (ru) * 2013-10-21 2018-10-31 Джиноско Замещенные пиримидиновые соединения и их применение в качестве syk ингибиторов
CA2974697A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Pyrimidine-2,4-(1h,3h)-dione derivatives and pharmaceutical compositions thereof and their use as inhibitors of monocarboxylate transporters
UY36586A (es) * 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
KR101712838B1 (ko) * 2016-03-17 2017-03-07 주식회사 골프존 가상 골프 시뮬레이션 장치, 가상 골프를 위한 영상 구현 방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록 매체
KR101730536B1 (ko) * 2016-03-17 2017-05-02 주식회사 골프존 스크린 골프 시스템에서 구현되는 컨텐츠 전송 서비스 방법, 컨텐츠 전송 서비스를 위한 모바일 단말기의 제어방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록매체
KR101712836B1 (ko) * 2016-03-17 2017-03-22 주식회사 골프존 가상 골프 시뮬레이션 장치, 가상 골프를 위한 영상 구현 방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록 매체
TWI823932B (zh) 2018-05-11 2023-12-01 中國大陸商迪哲(江蘇)醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US738495A (en) * 1902-12-26 1903-09-08 William E Sherwood Thill-coupling.
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
DE69807741T2 (de) 1997-12-05 2004-07-15 Astrazeneca Uk Ltd. Neuartige verbindungen
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
DK1107973T3 (da) * 1998-08-28 2004-02-23 Astrazeneca Ab Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi
JP2003531910A (ja) * 2000-05-04 2003-10-28 アストラゼネカ アクチボラグ チエノ[2,3−d]ピリミジンジオン類とそれらの医薬品としての使用
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
RU2332420C2 (ru) 2003-01-17 2008-08-27 Астразенека Аб Тиенопиримидиндионы и их применение в модулировании аутоиммунного заболевания
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
NO333702B1 (no) 2013-08-26
US7384951B2 (en) 2008-06-10
JP2006516974A (ja) 2006-07-13
MXPA05007496A (es) 2005-09-21
IL169370A0 (en) 2007-07-04
CA2512441A1 (en) 2004-08-05
EP1587812B1 (en) 2006-08-09
NO20053826D0 (no) 2005-08-15
KR101107486B1 (ko) 2012-01-19
DE602004001857D1 (de) 2006-09-21
EP1587812A1 (en) 2005-10-26
KR20110125256A (ko) 2011-11-18
CN1761672A (zh) 2006-04-19
ES2270337T3 (es) 2007-04-01
NZ541217A (en) 2008-05-30
RU2331647C2 (ru) 2008-08-20
PL214682B1 (pl) 2013-09-30
JP4519121B2 (ja) 2010-08-04
IS2376B (is) 2008-07-15
NO20053826L (no) 2005-10-17
AU2004206012B2 (en) 2007-06-14
BRPI0406801A (pt) 2006-01-17
ZA200505364B (en) 2006-09-27
CA2512441C (en) 2012-01-03
ATE335748T1 (de) 2006-09-15
BRPI0406801B8 (pt) 2021-05-25
CN100334093C (zh) 2007-08-29
IL169370A (en) 2011-05-31
DE602004001857T2 (de) 2007-05-24
WO2004065394A1 (en) 2004-08-05
AU2004206012A1 (en) 2004-08-05
SE0300119D0 (sv) 2003-01-17
KR20050092760A (ko) 2005-09-22
PL378222A1 (pl) 2006-03-20
UA81788C2 (uk) 2008-02-11
US20060052400A1 (en) 2006-03-09
HK1081959A1 (en) 2006-05-26
US20080214579A1 (en) 2008-09-04
BRPI0406801B1 (pt) 2018-04-03
IS7965A (is) 2005-07-29
RU2005121494A (ru) 2006-02-10

Similar Documents

Publication Publication Date Title
EG25613A (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
HK1048990A1 (en) Novel compounds.
PL366198A1 (en) Novel compounds
TW200508214A (en) Novel compounds
HK1084941A1 (en) Compounds and their use
CA2481723A1 (en) 5ht2c receptor modulators
DE602004021472D1 (en) Pyrimiidinverbindungen
MXPA04004498A (es) Derivados de n-adamantilmetil e intermediarios como composiciones farmaceuticas y procesos para su preparacion.
DE60116761D1 (en) Adamantanderivate
TW200613243A (en) Novel compounds
AU2003228770A8 (en) Substituted pyrazolopyrimidines
SE0300480D0 (sv) Novel compounds
SE0302139D0 (sv) Novel compounds
TW200604197A (en) New compounds
SE0402925D0 (sv) Novel Compounds
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
GB0104050D0 (en) Chemical compounds
GB0120461D0 (en) Novel compounds
IL172538A0 (en) Depsipeptide compounds, pharmaceutical compositions containing the same and processes for the preparation thereof
SE0303280D0 (sv) Novel compounds
MXPA02012426A (es) Compuestos nuevos.
DE60201074D1 (en) Pyrazolopyridinderivate
SE0202693D0 (sv) Compounds
SE0302755D0 (sv) Novel compounds
MXPA05007495A (es) Tienopiridazinonas y su uso en la modulacion de enfermedades autoinmunes.